| Citation: |
XIA Lin, YU Guozheng, TANG Jing. Diagnostic Value of Circular RNAs for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 864-870. DOI: 10.3971/j.issn.1000-8578.2021.21.0069
|
To systematically assess the diagnostic efficacy of circRNA in detecting CRC.
Eligible studies were obtained by searching the databases, such as PubMed, EMBASE, CNKI, etc. in line with the inclusion and exclusion criteria. Study quality and bias were judged by QUADAS-2 tool. The overall effect size, including pooled diagnostic parameters, was combined based on STATA 12.0 software. The causes of heterogeneity were investigated by conducting the subgroup, sensitivity and meta-regression analyses.
We included 17 eligible studies which contained 1873 CRC cases and 1573 paired controls. For CRC detection, circRNA expression harbored a pooled sensitivity, specificity and AUC of 0.79 (95%CI: 0.76-0.81), 0.69 (95%CI: 0.64-0.73) and 0.81, respectively. Subgroup analysis showed that serum-derived circRNA testing (AUC=0.89, DOR=16.79) harbored higher diagnostic efficacy than plasma (AUC=0.79, DOR=7.08) and tissue (AUC=0.76, DOR=6.87); oncogenic circRNAs achieved higher diagnostic capacity in detecting CRC than the anti-cancer circRNAs (AUC: 0.81 vs. 0.76; DOR: 8.54 vs. 6.21); however, circRNA testing quantified based on GAPDH showed comparable diagnostic capacity with the overall pooled effect.
Abnormally-expressed circRNAs have relatively high diagnostic efficacy in diagnosing CRC and may be rated as auxiliary biomarkers for CRC detection.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
|
| [2] |
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385. doi: 10.3322/caac.21565
|
| [3] |
钟选芳, 肖丹, 许岸高, 等. 粪便DNA与粪隐血试验机会性筛查大肠肿瘤的比较研究[J]. 临床消化病杂志, 2016, 28(2): 106-109. doi: 10.3870/1cxh.j.issn.1005-541X.2016.02.13
Zhong XF, Xiao D, Xu AG, et al. Fecal DNA versus fecal occult blood test in opportunity screening for colorectal neoplasm[J]. Lin Chuang Xiao Hua Bing Za Zhi, 2016, 28(2): 106-109. doi: 10.3870/1cxh.j.issn.1005-541X.2016.02.13
|
| [4] |
苏便欣, 张学彦. 结肠镜检查肠息肉漏诊及其相关因素研究进展[J]. 胃肠病学, 2016, 21(2): 115-117. doi: 10.3969/j.issn.1008-7125.2016.02.013
Su BX, Zhang XY. Advances in Studies on Missed Diagnosis of Intestinal Polyps and Related Factors in Colonoscopic Examination[J]. Wei Chang Bing Xue, 2016, 21(2): 115-117. doi: 10.3969/j.issn.1008-7125.2016.02.013
|
| [5] |
Connelly CM, Moon MH, Schneekloth JS Jr. The Emerging Role of RNA as a Therapeutic Target for Small Molecules[J]. Cell Chem Biol, 2016, 23(9): 1077-1090. doi: 10.1016/j.chembiol.2016.05.021
|
| [6] |
Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis[J]. Cell Res, 2015, 25(8): 981-984. doi: 10.1038/cr.2015.82
|
| [7] |
Hsiao KY, Lin YC, Gupta SK, et al. Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis[J]. Cancer Res, 2017, 77(9): 2339-2350. doi: 10.1158/0008-5472.CAN-16-1883
|
| [8] |
Li XN, Wang ZJ, Ye CX, et al. Circular RNA circVAPA is up-regulated and exerts oncogenic properties by sponging miR-101 in colorectal cancer[J]. Biomed Pharmacother, 2019, 112: 108611. doi: 10.1016/j.biopha.2019.108611
|
| [9] |
Li J, Ni S, Zhou C, et al. The expression profile and clinical application potential of hsa_circ_0000711 in colorectal cancer[J]. Cancer Manag Res, 2018, 10: 2777-2784. doi: 10.2147/CMAR.S172388
|
| [10] |
Ji W, Qiu C, Wang M, et al. Hsa_circ_0001649: A circular RNA and potential novel biomarker for colorectal cancer[J]. Biochem Biophys Res Commun, 2018, 497(1): 122-126. doi: 10.1016/j.bbrc.2018.02.036
|
| [11] |
Wang F, Wang J, Cao X, et al. Hsa_circ_0014717 is downregulated in colorectal cancer and inhibits tumor growth by promoting p16 expression[J]. Biomed Pharmacother, 2018, 98: 775-782. doi: 10.1016/j.biopha.2018.01.015
|
| [12] |
Wang J, Li X, Lu L, et al. Circular RNA hsa_circ_0000567 can be used as a promising diagnostic biomarker for human colorectal cancer[J]. J Clin Lab Anal, 2018, 32(5): e22379. doi: 10.1002/jcla.22379
|
| [13] |
Wang X, Zhang Y, Huang L, et al. Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances[J]. Int J Clin Exp Pathol, 2015, 8(12): 16020-16025. http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4730091&blobtype=pdf
|
| [14] |
Zhuo F, Lin H, Chen Z, et al. The expression profile and clinical significance of circRNA0003906 in colorectal cancer[J]. Onco Targets Ther, 2017, 10: 5187-5193. doi: 10.2147/OTT.S147378
|
| [15] |
Zhang P, Zuo Z, Shang W, et al. Identification of differentially expressed circular RNAs in human colorectal cancer[J]. Tumour Biol, 2017, 39(3): 1010428317694546. http://www.onacademic.com/detail/journal_1000039860885710_e0a6.html
|
| [16] |
Pan B, Qin J, Liu X, et al. Identification of Serum Exosomal hsa-circ_0004771 as a Novel Diagnostic Biomarker of Colorectal Cancer[J]. Front Genet, 2019, 10: 1096. doi: 10.3389/fgene.2019.01096
|
| [17] |
Ye DX, Wang SS, Huang Y, et al. A 3-circular RNA signature as a noninvasive biomarker for diagnosis of colorectal cancer[J]. Cancer Cell Int, 2019, 19: 276. doi: 10.1186/s12935-019-0995-7
|
| [18] |
Tian J, Xi X, Wang J, et al. CircRNA hsa_circ_0004585 as a potential biomarker for colorectal cancer[J]. Cancer Manag Res, 2019, 11: 5413-5423. doi: 10.2147/CMAR.S199436
|
| [19] |
Zhang W, Yang S, Liu Y, et al. Hsa_circ_0007534 as a blood-based marker for the diagnosis of colorectal cancer and its prognostic value[J]. Int J Clin Exp Pathol, 2018, 11(3): 1399-1406. http://ijcep.com/files/ijcep0070005.pdf
|
| [20] |
Yang N, Xu B, Kong P, et al. Hsa_circ_0002320: a novel clinical biomarker for colorectal cancer prognosis[J]. Medicine (Baltimore), 2020, 99(28): e21224. doi: 10.1097/MD.0000000000021224
|
| [21] |
Zhang J, Cai A, Zhao Y. Three CircRNAs Function as Potential Biomarkers for Colorectal Cancer[J]. Clin Lab, 2020, 66(12): 2405-2412.
|
| [22] |
Liang Y, Shi J, He Q, et al. Hsa_circ_0026416 promotes proliferation and migration in colorectal cancer via miR-346/NFIB axis[J]. Cancer Cell Int, 2020, 20: 494. doi: 10.1186/s12935-020-01593-1
|
| [23] |
Li J, Song Y, Wang J, et al. Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer detection[J]. Am J Transl Res, 2020, 12(11): 7395-7403. http://www.researchgate.net/publication/348347875_Plasma_circular_RNA_panel_acts_as_a_novel_diagnostic_biomarker_for_colorectal_cancer_detection
|
| [24] |
David Moher, Alessandro Liberati, Jennifer Tetzlaff, et al. 系统综述和荟萃分析优先报告的条目: PRISMA声明[J]. 中西医结合学报, 2009, 7(9): 889-896. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZX200909021.htm
David Moher, Alessandro Liberati, Jennifer Tetzlaff, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition)[J]. Zhong Xi Yi Jie He Xue Bao, 2009, 7(9): 889-896. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZX200909021.htm
|
| [25] |
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529-536. doi: 10.7326/0003-4819-155-8-201110180-00009
|
| [26] |
罗晓莉, 肖燕萍, 林颖烽, 等. 长链非编码RNA-UCA1对膀胱癌诊断价值的Meta分析[J]. 中国医药导报, 2019, 16(11): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201911020.htm
Luo XL, Xiao YP, Lin YF, et al. Meta-analysis of the value of long-chain non-coding RNA-UCA1 in the diagnosis of bladder cancer[J]. Zhongguo Yi Yao Dao Bao, 2019, 16(11): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201911020.htm
|
| [27] |
Huang X, Zhang W, Shao Z. Prognostic and diagnostic significance of circRNAs expression in hepatocellular carcinoma patients: A meta-analysis[J]. Cancer Med, 2019, 8(3): 1148-1156. doi: 10.1002/cam4.1939
|
| [28] |
Huang X, Zhang W, Shao Z. Prognostic and diagnostic significance of circRNAs expression in lung cancer[J]. J Cell Physiol, 2019, 234(10): 18459-18465. doi: 10.1002/jcp.28481
|
| [29] |
童峰, 陈坤, 何寒青. 优势比在诊断试验评价中的应用[J]. 中华流行病学杂志, 2005, 26(10): 813-814. doi: 10.3760/j.issn:0254-6450.2005.10.020
Tong F, Chen K, He HQ. Application of odds ratio in the evaluation of a diagnostic test[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2005, 26(10): 813-814. doi: 10.3760/j.issn:0254-6450.2005.10.020
|
| [30] |
王丹, 翟俊霞, 牟振云, 等. Meta分析中的异质性及其处理方法[J]. 中国循证医学杂志, 2009, 9(10): 1115-1118. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ200910015.htm
Wang D, Zhai JX, Mou ZY, et al. Discussing on the Research of Heterogeneity in Meta-analysis[J]. Zhongguo Xun Zheng Yi Xue Za Zhi, 2009, 9(10): 1115-1118. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ200910015.htm
|
| [31] |
李冬秀, 陈敬林, 黄湘, 等. 血清AFU对原发性肝癌诊断价值的meta分析[J]. 国际检验医学杂志, 2015, 1: 1-4. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201501003.htm
Li DX, Chen JL, Huang X, et al. Diagnostic value of serum AFU for primary hepatic carcinoma: a meta-analysis[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2015, 1: 1-4. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201501003.htm
|
| [1] | LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957 |
| [2] | SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158 |
| [3] | RAO Xionghui, LUO Hongliang, HUANG Jun, ZHU Zhengming. Prognostic and Clinicopathological Significance of PD-L1 Expression for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 1013-1021. DOI: 10.3971/j.issn.1000-8578.2019.19.0363 |
| [4] | CUI Gang, YAN Bin, TAO Yongguang. Effect of FDG-PET/CT in Diagnosis, Staging and Prognosis of Pancreatic Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 202-208. DOI: 10.3971/j.issn.1000-8578.2017.03.010 |
| [5] | TAN Yi, LIU Yan, SONG Yuwei, CHEN Qiufang, TAN Guoqiang, GUI Xiujuan, LIN Shaoqiang. Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 783-788. DOI: 10.3971/j.issn.1000-8578.2016.09.011 |
| [6] | YU Huihui, WEI Lixuan, LIU Yunyong, XING Xiaojing. Meta-analysis of Relationship Between Blood 25-hydroxyvitamin D Level and Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 394-398. DOI: 10.3971/j.issn.1000-8578.2015.04.017 |
| [7] | QU Yanli, WANG Haifeng, TANG Yong. Bevacizumab Combined with Chemotherapy as First-line Therapy for Metastatic Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1002-1008. DOI: 10.3971/j.issn.1000-8578.2014.09.011 |
| [8] | Yao Zhiwen, Zhao Zhenlong, Jiang Yumei, Mi Ying, Gu Miaoning. Meta-analysis for Association between Polymorphism of COX-2 -1195G>A and Colorectal Cancer Susceptibility[J]. Cancer Research on Prevention and Treatment, 2012, 39(02): 213-217. DOI: 10.3971/j.issn.1000-8578.2012.02.024 |
| [9] | LV Peng, HU Zhi-jian. A Meta Analysis on Relationship between Alcohol Dehydrogenase2 Polymorphisms and Risk of Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 579-583. DOI: 10.3971/j.issn.1000-8578.2011.05.027 |
| [10] | QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025 |
Figures(4) / Tables(4)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: